Poland· PL-100214880
Lamivudine Teva
A lamivudine product containing lamivudinum, registered in Poland by Teva B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lamivudine is registered in 17 of 19 countries.
Countries holding a registration under ATC J05AF05 (lamivudine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Lamivudine · ATC J05AF05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lamivudine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $2.42 in France to $7.71 in Switzerland — a ×3.2 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lamivudine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.71
- IT Italy$6.75
- FR France$2.42
The record
At a glance
URPL (Poland)- Active substance
- Lamivudinum
- Manufacturer
- Teva B.V.
- Country
- Poland (PL)
- ATC code
- J05AF05
- ATC class
- Lamivudine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909990725564
- gtin05909990725571
- gtin05909990725588
- gtin05909990725595
- gtin05909990725601
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
207 interactions on record for lamivudine.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lamivudine · interactions on record
207 records
- 6 severe
- 36 moderate
- 165 info
Most severe, free to view
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lamivudine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLAMIVUDIN TEVATeva B.V., Haarlem
- United StateslamivudineCamber Pharmaceuticals, Inc.
- ItalyLAMIVUDINA AUROBINDO ITALIAAUROBINDO PHARMA ITALIA S.R.L.
- SpainLAMIVUDINA ACCORD 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- NetherlandsLamivudine Accord 100 mg, filmomhulde tablettenAccord Healthcare B.V.
- BelgiumLamivudin Sandoz 100 mgSandoz
- IrelandLamivudine Teva 100 mg film-coated tabletsTeva Pharma B.V.
- SwitzerlandZeffix, FilmtablettenGlaxoSmithKline AG
Authorised across Europe · EMA
The same active substance is authorised in 12 EEA countries. Names it is sold under:
- Austria · Lamivudin Sandoz
- Cyprus · Lamivudine Normon
- Germany · Lamivudin Aurobindo, Lamivudin Mylan
- Spain · Lamivudina Accord, Lamivudina Aurovitas
- France · Lamivudine Arrow, Lamivudine Sandoz
- United Kingdom (Northern Ireland) · Lamivudine Amarox, Lamivudine Generics
- Iceland · Epivir, Lamivudine Teva
- Italy · Lamivudina Aurobindo, Lamivudina Aurobindo Italia
- Liechtenstein · Epivir, Lamivudine Teva
- Netherlands · Lamivudine Accord, Lamivudine Aurobindo
- Norway · Epivir, Lamivudine Teva
- Portugal · Lamivudina Aurobindo, Lamivudina Farmoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0e1b6da-246f-4707-b8ca-7561dc391cc0 GET /v1/drugs/c0e1b6da-246f-4707-b8ca-7561dc391cc0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "100 mg",
"packaging": "05909990725564 ¦ Rpz ¦ EU/1/09/566/001 ¦ 52728\n28 tabl.\n05909990725571 ¦ Rpz ¦ EU/1/09/566/002 ¦ 52729\n30 tabl.\n05909990725588 ¦ Rpz ¦ EU/1/09/566/003 ¦ 52730\n84 tabl.\n05909990725595 ¦ Rpz ¦ EU/1/09/566/004 ¦ 52732\n100 tabl.\n05909990725601 ¦ Rpz ¦ EU/1/09/566/005 ¦ 52733\n60 tabl.\nRpz ¦ EU/1/09/566/006 ¦ 148938\n60 tabl.",
"substance": "Lamivudinum 100 mg",
"common_name": "Lamivudinum",
"pl_product_id": "100214880",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lamivudine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.